News & Media
Learn more about the latest happenings at Otsuka. Select to see US news or read our press releases. You can also stay up to date with our global news in the link below.
![Image](/sites/g/files/qhldwo9046/files/styles/max_325x325/public/2020-11/image-full-bleed-copy%403x.jpg?itok=wwRC_Cyh)
Media Contact:
Senior Director, External Communications,
Otsuka America Pharmaceutical, Inc
ADPKD, the fourth leading cause of end-stage renal disease,[i],[ii] is a progressively debilitating genetic disease characterized by the development of fluid-filled cysts in the kidneys[iii]Data from two phase 3 clinical trials showed that JYNARQUE™ (tolvaptan) slowed kidney function decline in adults at risk of rapidly progressing ADPKDJYNARQUE can cause serious and potentially fatal liver
Princeton, New Jersey – In celebration of the vibrant startup community in Austin, TX, Otsuka America Pharmaceutical, Inc. (Otsuka) brought together innovators and startups in a live Pitch Event to spark the next generation of innovation in mental health care. Held at Elevate by Psych Congress, a gathering of up-and-coming leaders in mental health care, the event featured some of the most
Tokyo, Japan and Princeton, New Jersey - Otsuka Pharmaceutical Co., Ltd., and its indirect subsidiary Otsuka Pharmaceutical Development & Commercialization, Inc. (Otsuka), announce that the latter has been awarded a grant for up to US $10 million from the Bill & Melinda Gates Foundation to advance clinical development of Otsuka’s investigational compound to treat tuberculosis (TB),
New collaboration between the tech-enabled clinical research company and US mental health leader aims to transform clinical trials to accelerate patient access to innovative therapies PLAYA VISTA, CA. and ROCKVILLE, MD. (December 5, 2017) – Science 37, a trailblazing company focused on “site-less” clinical trials, and Otsuka Pharmaceutical Development & Commercialization, Inc.